title: Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
authors.forename: V
authors.initials: V
authors.lastname: Lopez
authors.forename: I
authors.initials: I
authors.lastname: Pinazo
authors.forename: N
authors.initials: N
authors.lastname: Marti
authors.forename: C
authors.initials: C
authors.lastname: Monteagudo
authors.forename: E
authors.initials: E
authors.lastname: Jorda
mesh_terms: D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006965:Hyperplasia / Q000139:chemically induced / Q000175:diagnosis; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D009536:Niacinamide / Q000031:analogs & derivatives; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000473:pathology*; D012871:Skin Diseases / Q000139:chemically induced* / Q000175:diagnosis; D012878:Skin Neoplasms / Q000473:pathology; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; C054368:fotemustine